SAM
CORT icon

Smartleaf Asset Management’s Corcept Therapeutics CORT Stock Holding History

Smartleaf Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.3K Hold
606
– – ﹤0.01% 1480
2026
Q1 		$23.1K Sell
606
-1,643
-73% -$61.4K ﹤0.01% 1866
2025
Q4 		$158K Buy
2,249
+224
+11% +$17.6K 0.01% 928
2025
Q3 		$170K Buy
2,025
+252
+14% +$18.2K 0.01% 793
2025
Q2 		$130K Sell
1,773
-415
-19% -$30.1K 0.01% 764
2025
Q1 		$120K Sell
2,188
-183
-8% -$11.1K 0.01% 762
2024
Q4 		$121K Buy
2,371
+1,795
+312% +$94.1K 0.01% 760
2024
Q3 		$25.3K Buy
576
+229
+66% +$8.14K ﹤0.01% 1223
2024
Q2 		$11.1K Buy
+347
New +$9.51K ﹤0.01% 1352

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smartleaf Asset Management's CORT Position: Q2 2026 in Review

Smartleaf Asset Management held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 606 shares worth $53.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1480.

Smartleaf Asset Management first reported a position in CORT in Q2 2024 and has held it in 9 quarters since. The position peaked at $170K in Q3 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Smartleaf Asset Management held 606 shares of Corcept Therapeutics worth $53.3K as of Q2 2026.
  • Smartleaf Asset Management left its Corcept Therapeutics share count unchanged in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1480 holding.
  • Smartleaf Asset Management first reported a position in Corcept Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Smartleaf Asset Management's Corcept Therapeutics position peaked at $170K in Q3 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.